We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Incorporating Conjugation-Ready Sites into Recombinant Antibodies
Product News

Incorporating Conjugation-Ready Sites into Recombinant Antibodies

Incorporating Conjugation-Ready Sites into Recombinant Antibodies
Product News

Incorporating Conjugation-Ready Sites into Recombinant Antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Incorporating Conjugation-Ready Sites into Recombinant Antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Abcam, a company based in life science reagents and tools, has announced a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company, covering the use of BrickBio’s proprietary platform for introducing conjugation-ready sites into antibodies and other proteins in both mammalian and bacterial expression systems.

Under the partnership, Abcam will have exclusive rights to the platform for the creation of novel conjugation-ready recombinant products for the research tools market, as well as rights to commercialize the platform across its recombinant antibody and protein portfolio for diagnostic use. In addition, Abcam will make a financial investment in BrickBio and work together with the BrickBio team to further industrialize the platform.

BrickBio’s platform provides the ability to site-selectively modify proteins in a broad range of eukaryotic and bacterial cell lines. Using a proprietary engineered tRNA synthetase/tRNA pair, the platform can readily incorporate unnatural amino acids that can then be coupled to a second molecule for labeling or other research applications or to create protein-conjugate therapeutics including antibody-drug conjugates.   


Advertisement